Robert Mróz
Impact in
-
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inhalation and Respiratory Drug Delivery
- Physiology top 10%
- Asthma and respiratory diseases
Papers in
-
- Chronic Obstructive Pulmonary Disease (COPD) Research 26
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 10
- Respiratory Support and Mechanisms 9
- Lung Cancer Treatments and Mutations 6
- Inhalation and Respiratory Drug Delivery 5
- Physiology 23
- Asthma and respiratory diseases 13
- Sarcoidosis and Beryllium Toxicity Research 5
- Co-authors
- E Chyczewska (32 shared papers)Adam Hołownia (20 shared papers)Jan J. Braszko (18 shared papers)William MacNee (6 shared papers)Ellen Drost (3 shared papers)Roel P. F. Schins (2 shared papers)Anna Stasiak‐Barmuta (7 shared papers)Esther García Gil (7 shared papers)
- Journals
- Advances in experimental medicine and biology (10 papers)European Respiratory Journal (3 papers)Cancers (3 papers)Respiratory Research (2 papers)Naunyn-Schmiedeberg s Archives of Pharmacology (2 papers)
- Partner nations
- PolandUnited StatesGermany
In The Last Decade
Robert Mróz
72 papers receiving 772 citations
Peers
Comparison fields: 5 of 116
- Pulmonary and Respiratory Medicine 392
- Physiology 256
- Cancer Research 98
- Developmental Neuroscience 22
- Health, Toxicology and Mutagenesis 70
Countries citing papers authored by Robert Mróz
This map shows the geographic impact of Robert Mróz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Mróz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Mróz more than expected).
Fields of papers citing papers by Robert Mróz
This network shows the impact of papers produced by Robert Mróz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Mróz. The network helps show where Robert Mróz may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Mróz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 79 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 109 | |
| 2 | 2013 | 87 | |
| 3 | Nanoparticle carbon black driven DNA damage induces growth arrest and AP-1 and NFkappaB DNA binding in lung epithelial A549 cell line. | 2007 | 51 |
| 4 | Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. | 2015 | 45 |
| 5 | Severe respiratory distress caused by central airway obstruction treated with self-expandable metallic stents. | 2008 | 29 |
| 6 | Molecular basis of chronic inflammation in lung diseases: new therapeutic approach. | 2007 | 27 |
| 7 | 2021 | 26 | |
| 8 | Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. | 2008 | 23 |
| 9 | Cytoplasm-nuclear trafficking of CREB and CREB phosphorylation at Ser133 during therapy of chronic obstructive pulmonary disease. | 2007 | 22 |
| 10 | 2019 | 21 | |
| 11 | 2014 | 17 | |
| 12 | 2009 | 17 | |
| 13 | 2019 | 16 | |
| 14 | Propofol protects rat astroglial cells against tert-butyl hydroperoxide-induced cytotoxicity; the effect on histone and cAMP-response-element-binding protein (CREB) signalling. | 2009 | 16 |
| 15 | 2009 | 15 | |
| 16 | 2024 | 14 | |
| 17 | Upregulation of Th1 cytokine profile in bronchoalveolar lavage fluid of patients with hypersensitivity pneumonitis. | 2008 | 12 |
| 18 | Chronic obstructive pulmonary disease: an update on nuclear signaling related to inflammation and anti-inflammatory treatment. | 2008 | 11 |
| 19 | 2023 | 11 | |
| 20 | 2021 | 11 |
About Robert Mróz
Robert Mróz is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Molecular Biology, Oncology and Cancer Research, having authored 79 papers that have together received 795 indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (26 papers), Asthma and respiratory diseases (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (10 papers), Respiratory Support and Mechanisms (9 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Sarcoidosis and Beryllium Toxicity Research (5 papers) and Inhalation and Respiratory Drug Delivery (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (392 citations), Physiology (256 citations), Cancer Research (98 citations), Developmental Neuroscience (22 citations) and Health, Toxicology and Mutagenesis (70 citations). Robert Mróz has collaborated with scholars based in Poland, United States and Germany. Frequent co-authors include E Chyczewska, Adam Hołownia, Jan J. Braszko, William MacNee, Ellen Drost, Roel P. F. Schins, Anna Stasiak‐Barmuta, Esther García Gil, Kenneth Donaldson and Ferran Chuecos. Their work appears in journals such as Advances in experimental medicine and biology, European Respiratory Journal, Cancers, Respiratory Research and Naunyn-Schmiedeberg s Archives of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.